English, Article edition: Post-Exposure Influenza Prophylaxis with Oseltamivir: Cost Effectiveness and Cost Utility in Families in the UK Beate Sander; Frederick G. Hayden; Marlene Gyldmark; ...

User activity

Share to:
 
Bookmark: http://trove.nla.gov.au/version/94629
Physical Description
  • article
Language
  • English

Edition details

Title
  • Post-Exposure Influenza Prophylaxis with Oseltamivir: Cost Effectiveness and Cost Utility in Families in the UK
Author
  • Beate Sander
  • Frederick G. Hayden
  • Marlene Gyldmark
  • Louis P. Garrison
Physical Description
  • article
Notes
  • Objectives: To assess the cost effectiveness and cost utility of preventing post-exposure influenza infection using the neuraminidase inhibitor oseltamivir from a healthcare payer's perspective in the UK. Methods: A simulation model was developed, based on clinical trial results and published data, to predict morbidity and mortality due to influenza and to compare oseltamivir post-exposure prophylaxis (PEP) with no prophylaxis within families with members aged >=​13 years. Two scenarios were tested: 1. Comparison of patients receiving PEP versus patients not receiving PEP and not being treated with oseltamivir should they become infected. 2. Comparison of patients receiving PEP versus patients not receiving PEP but being treated with oseltamivir should they become infected. The model was run with an attack rate in household contacts of 8% for the base case, with higher rates (up to 30%, representing pandemic conditions) tested in sensitivity analyses. A societal perspective and other key parameters were tested in sensitivity analysis. The year of costing was 2002. The time span for the model was up to 1 year (including one influenza season), but loss of life was included in the QALY calculation and based on expected life expectancy. Results: PEP with oseltamivir results in reduced morbidity (i.e. fewer influenza cases) and associated reductions in complications, hospitalisations and mortality due to influenza. When comparing oseltamivir PEP with no prophylaxis for contact attack rates of 8%, 12% and 30%, the mean costs per QALY gained for scenario one were estimated at Lstg 29_938, Lstg 18_697 and Lstg 5403, respectively; the mean costs per case avoided were Lstg 467, Lstg 293 and Lstg 84, respectively. The corresponding results for scenario two were Lstg 52_202, Lstg 31_610 and Lstg 9688 per QALY gained. Conclusions: PEP with oseltamivir is likely to be a cost-effective strategy for family contacts in the UK from a healthcare payer perspective when influenza-like illness contact attack rates are 8% or higher and the only treatment given is `usual care'.
  • Cost-effectiveness, Cost-utility, Influenza-virus-infections, Influenza-virus-infections, Oseltamivir
  • RePEc:wkh:phecon:v:24:y:2006:i:4:p:373-386
Language
  • English
Contributed by
OAIster

Get this edition

  • Set up My libraries

    How do I set up "My libraries"?

    In order to set up a list of libraries that you have access to, you must first login or sign up. Then set up a personal list of libraries from your profile page by clicking on your user name at the top right of any screen.

  • All (1)
  • Unknown (1)
None of your libraries hold this item.
None of your libraries hold this item.
None of your libraries hold this item.
None of your libraries hold this item.
None of your libraries hold this item.
None of your libraries hold this item.
None of your libraries hold this item.
None of your libraries hold this item.

User activity


e.g. test cricket, Perth (WA), "Parkes, Henry"

Separate different tags with a comma. To include a comma in your tag, surround the tag with double quotes.

Be the first to add a tag for this edition

Be the first to add this to a list

Comments and reviews

What are comments? Add a comment

No user comments or reviews for this version

Add a comment